How to appeal a Highmark diabetes drugs & insulin denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for diabetes drugs & insulin

Cited policy: BCBS External Insulin Infusion Pump Medical Policy (mirrors Medicare LCD L33464)

T1D OR insulin-requiring T2D meeting C-peptide / functional criteria; ≥3 injections/day or basal-bolus regimen; SMBG ≥4×/day or CGM; recent A1c documented; trained on pump.

How Highmark denies diabetes drugs & insulin — and how to counter it

Where Highmark pushes back: 1) Patient is Type 2 — pump not covered; 2) C-peptide above threshold; 3) No documentation of MDI failure.

Counter-arguments that hold up: LCD L33464 explicitly includes T2D meeting functional criteria (insulin deficiency, MDI ≥3/day, hypoglycemia, dawn phenomenon). ADA §7.20 supports CSII in selected T2D. Cite C-peptide value in fasting state with concurrent glucose.

What Highmark typically denies for diabetes drugs & insulin

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For diabetes drugs & insulin, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the diabetes drugs & insulin treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Rapid-acting analog insulin
• Basal analog insulin
• Pre-mixed insulin
• Concentrated insulin
• GLP-1 for T2D
• DPP-4 inhibitor

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.